Claims
- 1. A sustained-release drug dosage form comprising (1) granules of a drug which is terazosin or a salt or hydrate thereof coated with a sustained-release coating composition comprising from about 2 to about 20 weight percent (w/v) of an ethylcellulose or a methacrylic methylester, from about 0.1 to abut 5.0 weight percent (w/v) of a plasticizer and from about 0.5 to about 20 weight percent (w/v) of a detackifying agent and (2) a slow release matrix comprising at least one viscosity agent.
- 2. The drug dosage form of claim 1 wherein said plasticizer is selected from the group consisting of castor oil, propylene glycol, polyethylene glycol, acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate and tributyl citrate.
- 3. The drug dosage form of claim 1 wherein said detackifying agent is selected from the group consisting of magnesium stearate, talc, titanium dioxide and silica gel.
- 4. The drug dosage form of claim 1 wherein the coating composition comprises from about 2 to about 20 weight percent (w/v) of ethylcellulose, from about 0.1 to about 5.0 weight percent (w/v) of castor oil and from about 0.5 to about 20 weight percent (w/v) of magnesium stearate.
- 5. The drug dosage form of claim 1 wherein said drug is terazosin monohydrochloride dihydrate.
- 6. The drug dosage form of claim 1 wherein said viscosity agent is selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, povidone and hydroxypropylcellulose.
- 7. The dosage form of claim 1 comprising:
- from about 2.0 to about 80 weight percent sustained release coated drug granules;
- from about 0 to about 30 weight percent calcium phosphate;
- from about 2 to about 30 weight percent of a first viscosity agent and from about 0 to about 30 weight percent of a second viscosity agent wherein said first and second viscosity agents are independently selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, povidone and hydroxypropylcellulose.
- 8. The dosage form of claim 1 comprising:
- from about 2.6 to about 26.4 weight percent of sustained-release coated terazosin monohydrochloride dihydrate granules;
- about 2.5 weight percent of methylcellulose;
- about 10.5 weight percent of hydroxypropylmethylcellulose;
- about 34.0 weight percent of calcium phosphate;
- about 1.1 weight percent of stearic acid; and
- about 1.9 weight percent of talc.
- 9. The drug dosage form of claim 1 wherein said drug is R-(+)-terazosin monohydrochloride dihydrate.
Parent Case Info
This is a division of U.S. patent application Ser. No. 709,952, filed Jun. 4, 1991, now U.S. Pat. No. 5,169,642, a continuation-in-part of U.S. patent application Ser. No. 605,152, filed Nov. 2, 1990, (abandoned) which is a continuation-in-part of U.S patent application Ser. No. 444,458, filed Dec. 1, 1989,(abandoned) which is a continuation-in-part of U.S. patent application Ser. No. 353,809, filed May 22, 1989 (abandoned), which is a continuation-in-part of U.S. patent application Ser. No. 211,495, filed Jun. 24, 1988 (abandoned).
US Referenced Citations (19)
Foreign Referenced Citations (5)
Number |
Date |
Country |
2472788 |
May 1989 |
AUX |
092060 |
Oct 1983 |
EPX |
133110 |
Feb 1985 |
EPX |
347748 |
Dec 1989 |
EPX |
385846 |
May 1990 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
709952 |
Jun 1991 |
|
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
605152 |
Nov 1990 |
|
Parent |
444458 |
Dec 1989 |
|
Parent |
353809 |
May 1989 |
|
Parent |
211495 |
Jun 1988 |
|